PsychedelicNewsBreaks

TuesdayAug 15, 2023 12:37 pm

PsychedelicNewsBreaks – FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) to Present Phase 1 Data on Lucid-MS at Milan Peer Conference

FSD Pharma (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) is a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative and metabolic disorders. The company today announced that its late breaking abstract about phase 1 first-in-human data on Lucid-MS (Lucid-21-302) was selected for presentation at the upcoming MSMilan 2023 - 9th Joint ECTRIMS-ACTRIMS meeting scheduled for Oct. 11-13, 2023. “We are excited about presenting our phase 1 first-in-human clinical data on Lucid-MS at this peer conference in Milan,” said Andrzej Chruscinski, M.D., Ph.D., VP, clinical and scientific affairs, Lucid Psycheceuticals. “Current…

Continue Reading

TuesdayAug 08, 2023 1:37 pm

PsychedelicNewsBreaks — Mushrooms Inc. (MSRM) Transformative Mycelium Thread Tech Nears Completion, Filing for Patent Comes Next

Mushrooms (OTC: MSRM), a trailblazer in sustainable textile innovation, is in the final stages of filing a full patent application for its groundbreaking mycelium thread technology. Filing for the patent is part of the company’s mission to revolutionize the textile industry and represents a significant stride toward a more sustainable and ecologically conscious future while also advancing science and technology. According to the company, the unique characteristics of the mycelium thread position it as a “transformative force” across diverse sectors, including applications in the medical, military, aerospace, lifestyle and environmental spaces. The announcement noted that when natural properties of mycelium are…

Continue Reading

ThursdayAug 03, 2023 3:09 pm

PsychedelicNewsBreaks — Green Label Summit 2023 to Showcase Insights and Innovations Shaping the Future of Cannabis

The highly-anticipated Green Label Summit 2023, hosted by Jotia Group, is set to shine in the shimmering lights of Las Vegas on Sept. 13 - 14 at The Expo, World Market Center. The event is designed to deliver an unparalleled platform for dynamic discussions and visionary insights into the ever-evolving cannabis industry. The summit will feature the Psychedelic Horizons Forum, captivating sessions and masterclasses, with a special emphasis on the future of cannabis. Throughout the event, experts will share invaluable market predictions and insights into medical advancements, product development, evolving regulations, consumer choices, tourism, cultivation and growing green, and cutting-edge…

Continue Reading

ThursdayAug 03, 2023 11:22 am

PsychedelicNewsBreaks – FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) UNBUZZD Definitive Agreement Featured by Investment Pitch Media

FSD Pharma (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative, inflammatory and metabolic disorders, is spotlighted on the latest InvestmentPitch Media release. The media release discusses FSD Pharma’s recently executed definitive agreement that grants exclusive rights to Celly Nutrition for recreational applications of its alcohol misuse technology and the launch of UNBUZZD(TM), a revolutionary rapid alcohol detoxification drink. According to the agreement, Celly Nu will pay FSD a license fee by issuing 100,000,000 shares and a 7% royalty on gross revenue if…

Continue Reading

WednesdayAug 02, 2023 12:53 pm

PsychedelicNewsBreaks – FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) Enters Agreement to Launch UNBUZZD

FSD Pharma (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) is a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative and metabolic disorders. The company today announced its entry into a definitive agreement with Celly Nutrition Inc. to grant exclusive rights to recreational applications for FSD Pharma’s alcohol misuse technology and launch UNBUZZD. A revolutionary, rapid alcohol detoxification drink, UNBUZZD was created by scientists and the expert clinical research team at FSD Pharma. “This is a major milestone for our company,” said Zeeshan Saeed, founder, CEO and executive co-chairman of the…

Continue Reading

ThursdayJul 20, 2023 1:29 pm

PsychedelicNewsBreaks – Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Announces Results from ‘Groundbreaking’ Sponsored Study Measuring Psychedelic Effects

Cybin (NEO: CYBN) (NYSE American: CYBN), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative psychedelic-based treatment options, is reporting on the release of study findings. Cybin sponsored the study, which was conducted by Kernel, a leader in noninvasive neuroimaging. Titled “Measuring acute effects of subanesthetic ketamine on cerebrovascular hemodynamics in humans using TD-fNIRS,” the study was published in “Scientific Reports from the Nature Portfolio of Journals” and evaluated the ability of Kernel’s Flow1 system to capture and analyze brain changes resulting from the administration of a psychoactive substance. According to the announcement, the single-blind, placebo-controlled…

Continue Reading

WednesdayJul 19, 2023 2:04 pm

PsychedelicNewsBreaks – Mushrooms Inc. (MSRM) Featured in Psychedelic Spotlight Podcast

Mushrooms Inc. (OTC: MSRM) today announced that the company’s CEO Kimberly Carlson recently appeared on the esteemed Psychedelic Spotlight Podcast to discuss the exciting potential of the industrial mushroom industry. Mushrooms Inc., the first company trading on the U.S. stock market focused on the industrial side of mushrooms, is leading the way in revolutionizing this emerging sector. During the podcast episode hosted by David Flores, the CEO of Psychedelic Spotlight, Carlson shared insights into the vision and mission of Mushrooms Inc. The company, with a commitment to environmentally beneficial products, is dedicated to supporting the growth of the mushroom industry…

Continue Reading

TuesdayJul 18, 2023 1:01 pm

PsychedelicNewsBreaks – FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) Reports Arbitration Panel Finding in Syneos Health (NASDAQ: SYNH) Proceeding

FSD Pharma (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative, inflammatory and metabolic disorders, is reporting that an arbitration panel has found that Syneos Health (NASDAQ: SYNH) failed to use commercially reasonable efforts in conducting its trial for FSD 201. According to the announcement, Syneos Health filed an arbitration proceeding against FSD Pharma in 2022. Syneos claimed that FSD Pharma owed Syneos Health $3,915,388.69 in damages as well as interest on that amount in relation to a failed phase 2 FDA trial…

Continue Reading

MondayJul 17, 2023 1:09 pm

PsychedelicNewsBreaks – Institute of Biomedical Research Corp. (MRES) Unveils Meticulously Crafted Line of Teas Sourced from Kenya

Institute of Biomedical Research (OTC: MRES) (doing business as M2Bio Sciences) is a nutraceutical biotechnology company focused on alternative plant-based cannabinoids, medical psilocybin and mental health therapeutic research powered by artificial intelligence and evidence-based sustainable products and solutions. M2Bio Sciences today announced the forthcoming launch of a captivating line of teas sourced from the scenic gardens of Kenya. The meticulously crafted collection provides not only an exquisite sensory experience but also delivers exceptional medicinal health benefits. “We are delighted to introduce our exceptional line of purple, white and green teas from Kenya,” said Jeff Robinson, CEO of M2Bio Sciences. “Our…

Continue Reading

FridayJun 30, 2023 1:44 pm

PsychedelicNewsBreaks – FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) Shares Results Shareholder Annual General and Special Meeting

FSD Pharma (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative, inflammatory and metabolic disorders, recently held its annual general and special meeting of shareholders. The virtual-only meeting was held on June 29, 2023. The company is reporting on the results of the meeting, including the election of all nominees for directors of the company. Those nominees included Anthony Durkacz, Zeeshan Saeed, Dr. Lakshmi P. Kotra, Adnan Bashir, Nitin Kaushal, Michael (Zappy) Zapolin and Dr. Eric Hoskins. The directors will serve until the…

Continue Reading